Chand N, Harrison J E, Sofia R D
Wallace Laboratories, Division of Carter-Wallace, Inc., Cranbury, New Jersey 08512.
Res Commun Mol Pathol Pharmacol. 1994 Oct;86(1):75-82.
Aeroallergen-induced eosinophilia in actively sensitized guinea pigs was used as a marker of bronchial inflammation in this study. Drugs were administered p.o. therapeutically, i.e., four hours after aeroallergen challenge. Allergic bronchial eosinophilia in guinea pigs was sensitive to dexamethasone. Thus, the therapeutic approach appears to be a reliable, predictable, and sensitive for the evaluation and selection of potential bronchial anti-inflammatory compounds. PAF-antagonists (WEB-2086, WEB-2170, and E-6123) and a 5-lipoxygenase inhibitor (E-6080) did not influence allergen-induced eosinophil infiltration in the bronchoalveolar lavage fluid. These observations seem to suggest that therapeutic administration of PAF antagonists and leukotriene synthesis inhibitors exert little or no inhibitory effect on the progression of late-phase allergic bronchial inflammation in this model.
在本研究中，将变应原诱导的主动致敏豚鼠嗜酸性粒细胞增多用作支气管炎症的标志物。药物经口服给药进行治疗，即在变应原激发后4小时给药。豚鼠的过敏性支气管嗜酸性粒细胞增多对地塞米松敏感。因此，该治疗方法似乎对于评估和选择潜在的支气管抗炎化合物是可靠、可预测且敏感的。血小板活化因子拮抗剂（WEB-2086、WEB-2170和E-6123）以及5-脂氧合酶抑制剂（E-6080）不影响变应原诱导的支气管肺泡灌洗液中的嗜酸性粒细胞浸润。这些观察结果似乎表明，在该模型中，血小板活化因子拮抗剂和白三烯合成抑制剂的治疗性给药对迟发性过敏性支气管炎症的进展几乎没有抑制作用。
